Blood MSI dynamics as a predictive biomarker of immune checkpoint inhibitor therapy efficacy in colorectal cancer (CRC): preliminary results from an observational trial

被引：0
|
作者：
Byakhova, M. [1 ]
Veselovsky, E. [1 ]
Yudina, V. [1 ]
Kuznetsova, O. [1 ]
Kravchuk, D. [1 ]
Lebedeva, A. [1 ]
Belova, E. [1 ]
Taraskina, A. [1 ]
Grigoreva, T. [1 ]
Kavun, A. [1 ]
Nikulin, V. [1 ]
Mileyko, V. [1 ]
Tryakin, A. [1 ]
Fedyanin, M. [1 ]
Ivanov, M. [1 ]
机构：
[1] City Clin Oncol Hosp 1, Novosibirsk, Russia
来源：
VIRCHOWS ARCHIV | 2024年 / 485卷
基金：
俄罗斯科学基金会;
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
E-PS-19-01
引用
收藏
页码：S422 / S422
页数：1
相关论文
共 50 条
  • [21] A phase 1b study of NC410 in combination with pembrolizumab in immune checkpoint inhibitor (ICI) naive, and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer.
    Christenson, Eric
    Mahadevan, Daruka
    Kazmi, Syed Mohammad Ali
    Manda, Sudhir
    Sohal, Davendra
    Hutson, Thomas E.
    Fu, Siqing
    Martz, Ashley
    Kordahi, Stephanie
    Barbu, Emilia Alina
    Flies, Dallas
    Langermann, Solomon
    Chisamore, Michael Jon
    Gutierrez, Martin
    Matrana, Marc Ryan
    Spira, Alex
    Wadlow, Raymond Couric
    Guha, Udayan
    Myint, Han
    Le, Dung T.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [22] Predictive biomarkers of chemotherapy efficacy in colorectal cancer: Results from the UK MRC FOCUS trial (vol 26, pg 2690, 2008)
    Braun
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (26) : 4363 - 4363
  • [23] An observational/translational study of BRAF inhibitor combination therapy for BRAF-mutant metastatic colorectal cancer including biomarker research: BEETS trial (JACCRO CC-18)
    Sunakawa, Y.
    Inagaki, C.
    Yuki, S.
    Shiozawa, M.
    Tsuji, A.
    Matoba, R.
    Inoue, E.
    Muro, K.
    Ichikawa, W.
    ANNALS OF ONCOLOGY, 2022, 33 : S267 - S267
  • [24] Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy Guideline From the College of American Pathologists in Collaboration With the Association for Molecular Pathology and Fight Colorectal Cancer
    Bartley, Angela N.
    Mills, Anne M.
    Konnick, Eric
    Overman, Michael
    Ventura, Christina B.
    Souter, Lesley
    Colasacco, Carol
    Stadler, Zsofia K.
    Kerr, Sarah
    Howitt, Brooke E.
    Hampel, Heather
    Adams, Sarah F.
    Johnson, Wenora
    Magi-Galluzzi, Cristina
    Sepulveda, Antonia R.
    Broaddus, Russell R.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2022, 146 (10) : 1194 - 1210
  • [25] PRELIMINARY SAFETY AND EFFICACY RESULTS FROM THE MULTICENTRE OTILIA OBSERVATIONAL STUDY OF BEVACIZUMAB-CONTAINING THERAPY IN WOMEN WITH NEWLY DIAGNOSED OVARIAN CANCER IN GERMANY
    Wimberger, P.
    Mustea, A.
    Oskay-Oezcelik, G.
    Meinerz, W.
    Reichert, D.
    Forstbauer, H.
    Keller, M.
    Frank, M.
    Klawitter, S.
    Kiewitz, C.
    Mueller, M.
    Sehouli, J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 31 - 32
  • [26] Prognostic and predictive blood-based biomarkers of overall survival (OS) in patients (pts) with advanced colorectal cancer (CRC) treated with cetuximab (C): Results from CALGB 80203 (Alliance)
    Hatch, Ace J.
    Pang, Herbert
    Starr, Mark D.
    Brady, John C.
    Jia, Jingquan
    Niedzwiecki, Donna
    Venook, Alan Paul
    Cushman, Stephanie M.
    Hurwitz, Herbert
    Nixon, Andrew B.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [27] Prognostic and predictive blood-based biomarkers of overall survival (OS) in patients (pts) with advanced colorectal cancer (CRC) treated with cetuximab (C): Results from CALGB 80203 (Alliance).
    Hatch, Ace Joseph
    Pang, Herbert
    Starr, Mark D.
    Brady, John C.
    Jia, Jingquan
    Jiang, Chen
    Sibley, Alexander
    Owzar, Kouros
    Niedzwiecki, Donna
    Venook, Alan P.
    Cushman, Stephanie M.
    Hurwitz, Herbert
    Nixon, Andrew B.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [28] Efficacy and outcomes of ramucirumab and docetaxel in patients with metastatic non-small cell lung cancer after disease progression on immune checkpoint inhibitor therapy: Results of a monocentric, retrospective analysis
    Kareff, Samuel A.
    Gawri, Kunal
    Khan, Khadeja
    Kwon, Deukwoo
    Rodriguez, Estelamari
    Lopes, Gilberto de Lima
    Dawar, Richa
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [29] Efficacy and safety of anlotinib plus docetaxel in non-small cell lung cancer (NSCLC) after failure of previous immune checkpoint inhibitors (ICIs) therapy: Results from a phase I/II trial
    Fang, Y.
    Pan, H.
    Shou, J.
    Hong, W.
    Chen, J.
    Wang, Y.
    Guo, Q.
    Lu, L.
    Rao, C.
    Yang, X.
    Zhu, D.
    Lan, F.
    ANNALS OF ONCOLOGY, 2021, 32 : S1021 - S1021
  • [30] Predictive Efficacy of Blood-Based Tumor Mutation Burden Assay for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
    Zhang, Nan
    Zhang, Jinwei
    Wang, Guoqing
    He, Xin
    Mi, Yin
    Cao, Ying
    Yu, Xiaoxu
    FRONTIERS IN ONCOLOGY, 2022, 12
12345